6α-Ethyl-Chenodeoxycholic Acid (6-ECDCA), a Potent and Selective FXR Agonist Endowed with Anticholestatic Activity
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
A series of 6alpha-alkyl-substituted analogues of chenodeoxycholic acid (CDCA) were synthesized and evaluated as potential farnesoid X receptor (FXR) ligands. Among them, 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA) was shown to be a very potent and selective FXR agonist (EC(50) = 99 nM) and to be endowed with anticholeretic activity in an in vivo rat model of cholestasis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A bile acid receptor (FXR) agonist has reached the market since this programme started: obeticholic acid (Ocaliva), which was discovered by GSK in collaboration with the University of Perugia51 and subsequently developed by Intercept Pharmaceuticals.”
From Unexplored therapeutic opportunities in the human genome (2018) · cites this paper as [51]
In the citing paper
“OCA is a farnesoid X receptor (FXR) agonist that is 100 times more potent than the endogenous ligand, chenodeoxycholic acid.(156)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [156]
In the citing paper
“Obeticholic acid has approximately 100 times greater potency in activating FXR than chenodeoxycholic acid. 11”
From A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis (2016) · cites this paper as [11]
In the citing paper
“Obeticholic acid is a selective farnesoid X receptor (FXR) agonist that is derived from the bile acid chenodeoxycholic acid, the endogenous FXR ligand.”
From A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis (2016) · cites this paper as [11]
In the citing paper
“OCA, a 6α-ethyl derivate of chenodeoxycholic acid, is a steroidal FXR agonist (still maintaining its BA structure) and first-in-class therapeutic FXR ligand.94”
From Novel therapeutic targets for cholestatic and fatty liver disease (2022) · cites this paper as [94]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Identification of a nuclear receptor for bile acids
Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., Hull, M. V., Lustig, K. D., Mangelsdorf, D. J., & Shan, B. (1999) · Science · doi:10.1126/science.284.5418.1362 · Cited by 2,714
Bile Acids: Natural Ligands for an Orphan Nuclear Receptor
Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., et al. (1999) · Science · doi:10.1126/science.284.5418.1365 · Cited by 2,274
Self-citationNuclear Receptors and Lipid Physiology: Opening the X-Files
Chawla, A., Repa, J. J., Evans, R. M., & Mangelsdorf, D. J. (2001) · Science · doi:10.1126/science.294.5548.1866 · Cited by 2,085
A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis
Goodwin, B., Jones, S. A., Price, R. R., Watson, M. A., McKee, D. D., Moore, L. B., Galardi, C., Wilson, J. G., Lewis, M. C., Roth, M. E., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00051-4 · Cited by 1,940
Self-citationTargeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819
Endogenous Bile Acids Are Ligands for the Nuclear Receptor FXR/BAR
Wang, H., Chen, J., Hollister, K., Sowers, L. C., & Forman, B. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80348-2 · Cited by 1,636
Combinatorial Control of Gene Expression by Nuclear Receptors and Coregulators
McKenna, N. J., & O'Malley, B. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00641-4 · Cited by 1,463
The Continuing Importance of Bile Acids in Liver and Intestinal Disease
Hofmann, A. F. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.22.2647 · Cited by 982
Modulation of Polyketide Synthase Activity by Accessory Proteins During Lovastatin Biosynthesis
Kennedy, J., Auclair, K., Kendrew, S. G., Park, C., Vederas, J. C., & Richard Hutchinson, C. (1999) · Science · doi:10.1126/science.284.5418.1368 · Cited by 654
Identification of a Chemical Tool for the Orphan Nuclear Receptor FXR
Maloney, P. R., Parks, D. J., Haffner, C. D., Fivush, A. M., Chandra, G., Plunket, K. D., Creech, K. L., Moore, L. B., Wilson, J. G., Lewis, M. C., et al. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm0002127 · Cited by 527
Self-citation
Research works printed but not linked: 3
- Mangelsdorf D. J., 1995, Cell, 83, 850
- Forman B. M., 1995, Cell, 81, 693
- Lu T. T., 2000, Mol. Cell, 6, 515
Cited by
Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
Lefebvre, P., Cariou, B., Lien, F., Kuipers, F., & Staels, B. (2009) · Physiological Reviews · doi:10.1152/physrev.00010.2008 · Cited by 1,678
“thus classified as an agonist (EC50 8 M) (190, 232, 237, 359), DCA, LCA, and CA were inactive in this assay”
BackgroundMethodTargeting bile‐acid signalling for metabolic diseases
Thomas, C., Pellicciari, R., Pruzanski, M., Auwerx, J., & Schoonjans, K. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2619 · Cited by 1,422
Self-citationA Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509840 · Cited by 1,131
“Urinary tract infection 8 (11) 4 (6) 4 (5) 31 (16)”
Mudaliar, S., Henry, R. R., Sanyal, A. J., Morrow, L., Marschall, H., Kipnes, M., Adorini, L., Sciacca, C. I., Clopton, P., Castelloe, E., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.05.042 · Cited by 931
“Obeticholic acid (OCA; INT-747), a 6a-ethyl derivative of chenodeoxycholic acid, is a first-in-class selective FXR agonist with anticholestatic and hepatoprotective properties.(26) OCA shows 100-fold greater FXR agonistic activity than chenodeoxycholic acid, the natural FXR agonist in humans.”
BackgroundLindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913
“OCA is a Farnesoid X Receptor (FXR) agonist that is 100 times more potent than the endogenous ligand, chenodeoxycholic acid.(156) Through FXR activation, OCA modulates bile acid synthesis, absorption, transport, secretion, and metabolism, with a net effect of choleresis.”
BackgroundGadaleta, R. M., van Erpecum, K. J., Oldenburg, B., Willemsen, E. C. L., Renooij, W., Murzilli, S., Klomp, L. W. J., Siersema, P. D., Schipper, M. E. I., Danese, S., et al. (2011) · Gut · doi:10.1136/gut.2010.212159 · Cited by 870
Bile Acids: Chemistry, Pathochemistry, Biology, Pathobiology, and Therapeutics
Hofmann, A. F., & Hagey, L. R. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-7568-6 · Cited by 859
Dietary metabolism, the gut microbiome, and heart failure
Tang, W. H. W., Li, D. Y., & Hazen, S. L. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0108-7 · Cited by 789
Duell, P. B., Welty, F. K., Miller, M., Chait, A., Hammond, G., Ahmad, Z., Cohen, D. E., Horton, J. D., Pressman, G. S., Toth, P. P., et al. (2022) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000153 · Cited by 727
Bile acid receptors as targets for drug development
Schaap, F. G., Trauner, M., & Jansen, P. L. M. (2014) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.151 · Cited by 696
Mouries, J., Brescia, P., Silvestri, A., Spadoni, I., Sorribas, M., Wiest, R., Mileti, E., Galbiati, M., Invernizzi, P., Adorini, L., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.08.005 · Cited by 688
Natural product and natural product derived drugs in clinical trials
Butler, M. S., Robertson, A. A. B., & Cooper, M. A. (2014) · Nat. Prod. Rep. · doi:10.1039/c4np00064a · Cited by 602
Hirschfield, G. M., Mason, A., Luketic, V., Lindor, K., Gordon, S. C., Mayo, M., Kowdley, K. V., Vincent, C., Bodhenheimer, H. C., Parés, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.12.005 · Cited by 576
Bile Acids Activated Receptors Regulate Innate Immunity
Fiorucci, S., Biagioli, M., Zampella, A., & Distrutti, E. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01853 · Cited by 562
Self-citationBile Acid Metabolism in Liver Pathobiology
Chiang, J. Y. L., & Ferrell, J. M. (2018) · Gene Expression · doi:10.3727/105221618x15156018385515 · Cited by 546
New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond
Beuers, U., Trauner, M., Jansen, P., & Poupon, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.023 · Cited by 537
“In liver disease this regulation may be insufficient or may have gone astray and this prompted researchers to design BA analogues and non-BA compounds with high FXR affinity [108–112].”
BackgroundStructural Overview of the Nuclear Receptor Superfamily: Insights into Physiology and Therapeutics
Huang, P., Chandra, V., & Rastinejad, F. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135917 · Cited by 533
The Farnesoid X Receptor: A Molecular Link Between Bile Acid and Lipid and Glucose Metabolism
Claudel, T., Staels, B., & Kuipers, F. (2005) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000178994.21828.a7 · Cited by 504
Bile acid nuclear receptor FXR and digestive system diseases
Ding, L., Yang, L., Wang, Z., & Huang, W. (2015) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2015.01.004 · Cited by 477
Fiorucci, S., Antonelli, E., Rizzo, G., Renga, B., Mencarelli, A., Riccardi, L., Orlandi, S., Pellicciari, R., & Morelli, A. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.08.001 · Cited by 472
Self-citationMolecular physiology of bile acid signaling in health, disease, and aging
Perino, A., Demagny, H., Velazquez-Villegas, L., & Schoonjans, K. (2021) · Physiological Reviews · doi:10.1152/physrev.00049.2019 · Cited by 481
The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer
Sun, L., Cai, J., & Gonzalez, F. J. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00404-2 · Cited by 435
Bile Acids as Metabolic Regulators and Nutrient Sensors
Chiang, J. Y. L., & Ferrell, J. M. (2019) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-082018-124344 · Cited by 437
“OCA decreases bile acid synthesis and alleviates inflammation in experimental cholestasis (105); however, increased serum LDL cholesterol and decreased high-density lipoprotein cholesterol may result.”
BackgroundPuri, P., Daita, K., Joyce, A., Mirshahi, F., Santhekadur, P. K., Cazanave, S., Luketic, V. A., Siddiqui, M. S., Boyett, S., Min, H., et al. (2018) · Hepatology · doi:10.1002/hep.29359 · Cited by 426
Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies
Musso, G., Cassader, M., & Gambino, R. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.3 · Cited by 412
Unexplored therapeutic opportunities in the human genome
Oprea, T. I., Bologa, C. G., Brunak, S., Campbell, A., Gan, G. N., Gaulton, A., Gomez, S. M., Guha, R., Hersey, A., Holmes, J., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.14 · Cited by 378
Liu, Y., Binz, J., Numerick, M. J., Dennis, S., Luo, G., Desai, B., MacKenzie, K. I., Mansfield, T. A., Kliewer, S. A., Goodwin, B., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18945 · Cited by 398
A Chemical, Genetic, and Structural Analysis of the Nuclear Bile Acid Receptor FXR
Downes, M., Verdecia, M. A., Roecker, A. J., Hughes, R., Hogenesch, J. B., Kast-Woelbern, H. R., Bowman, M. E., Ferrer, J.-L., Anisfeld, A. M., Edwards, P. A., et al. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00104-7 · Cited by 390
“Furthermore, it was demonstrated that either a methyl substituent or a bulkier group at this position reduced efficacy (Pellicciari et al., 2002).”
BackgroundMethodFXR: a metabolic regulator and cell protector
Wang, Y.-D., Chen, W.-D., Moore, D. D., & Huang, W. (2008) · Cell Research · doi:10.1038/cr.2008.289 · Cited by 389
FXR signaling in the enterohepatic system
Matsubara, T., Li, F., & Gonzalez, F. J. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.05.004 · Cited by 381
“…et al. (2000) GW9047 2001 Agonist 1,1-Bisphosphonate esters Aromatics Synthesis Niesor et al. (2001) 2002 Agonist 6-ECDCA Steroid Semi-synthesis Pellicciari et al. (2002) 2003 Agonist Fexaramine Aromatics Synthesis Downes et al. (2003) 2003 Antagonist Guggulsterone Steroid Nature Urizar et al.…”
BackgroundInfluentialAn Intestinal Microbiota–Farnesoid X Receptor Axis Modulates Metabolic Disease
Gonzalez, F. J., Jiang, C., & Patterson, A. D. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.08.057 · Cited by 372
Hofmann, A. F., & Hagey, L. R. (2014) · Journal of Lipid Research · doi:10.1194/jlr.r049437 · Cited by 358
Apoptosis and Necrosis in the Liver
Guicciardi, M. E., Malhi, H., Mott, J. L., & Gores, G. J. (2013) · Comprehensive Physiology · doi:10.1002/cphy.c120020 · Cited by 353
Fiorucci, S., Mencarelli, A., Palladino, G., & Cipriani, S. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.08.001 · Cited by 346
Self-citationBile Acid Metabolism and Signaling in Cholestasis, Inflammation, and Cancer
Li, T., & Apte, U. (2015) · Advances in Pharmacology · doi:10.1016/bs.apha.2015.04.003 · Cited by 333
“OCA is a 6α-ethyl CDCA derivative that selectively activates FXR with a 100-fold higher potency than CDCA (Pellicciari et al., 2004, 2002).”
BackgroundZollner, G., Marschall, H.-U., Wagner, M., & Trauner, M. (2006) · Molecular Pharmaceutics · doi:10.1021/mp060010s · Cited by 335
Structural Basis for Bile Acid Binding and Activation of the Nuclear Receptor FXR
Mi, L.-Z., Devarakonda, S., Harp, J. M., Han, Q., Pellicciari, R., Willson, T. M., Khorasanizadeh, S., & Rastinejad, F. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00112-6 · Cited by 307
Self-citationGeier, A., Wagner, M., Dietrich, C. G., & Trauner, M. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2006.04.014 · Cited by 314
Erratum: Unexplored therapeutic opportunities in the human genome
Oprea, T. I., Bologa, C. G., Brunak, S., Campbell, A., Gan, G. N., Gaulton, A., Gomez, S. M., Guha, R., Hersey, A., Holmes, J., et al. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.52 · Cited by 311
Primary biliary cholangitis: pathogenesis and therapeutic opportunities
Gulamhusein, A. F., & Hirschfield, G. M. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0226-7 · Cited by 308
Bile acid metabolism and signaling in liver disease and therapy
Chiang, J. Y. L. (2017) · Liver Research · doi:10.1016/j.livres.2017.05.001 · Cited by 294
“OCA treatment displayed effective protection in experimental cholestasis models [66, 69].”
BackgroundDeciphering the nuclear bile acid receptor FXR paradigm
Modica, S., Gadaleta, R. M., & Moschetta, A. (2010) · Nuclear Receptor Signaling · doi:10.1621/nrs.08005 · Cited by 295
“Its activity in this transcriptional assay was three times higher than CDCA with EC50=99 nM [Pellicciari et al., 2002].”
InfluentialDiscovery of farnesoid X receptor and its role in bile acid metabolism
Chiang, J. Y. L., & Ferrell, J. M. (2022) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2022.111618 · Cited by 288
Zhang, S., Wang, J., Liu, Q., & Harnish, D. C. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.03.025 · Cited by 290
Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease
Porez, G., Prawitt, J., Gross, B., & Staels, B. (2012) · Journal of Lipid Research · doi:10.1194/jlr.r024794 · Cited by 286
A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis
Kowdley, K. V., Luketic, V., Chapman, R., Hirschfield, G. M., Poupon, R., Schramm, C., Vincent, C., Rust, C., Parés, A., Mason, A., et al. (2018) · Hepatology · doi:10.1002/hep.29569 · Cited by 281
Wagner, M., Fickert, P., Zollner, G., Fuchsbichler, A., Silbert, D., Tsybrovskyy, O., Zatloukal, K., Guo, G. L., Schuetz, J. D., Gonzalez, F. J., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)01068-0 · Cited by 264
Pellicciari, R., Gioiello, A., Macchiarulo, A., Thomas, C., Rosatelli, E., Natalini, B., Sardella, R., Pruzanski, M., Roda, A., Pastorini, E., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901390p · Cited by 260
Self-citationVerbeke, L., Farre, R., Trebicka, J., Komuta, M., Roskams, T., Klein, S., Elst, I. V., Windmolders, P., Vanuytsel, T., Nevens, F., et al. (2014) · Hepatology · doi:10.1002/hep.26939 · Cited by 258
“50% effective concentration of 99 nM, which is 100 times more potent than its endogenous ligand, chenodeoxycholic acid.(45,46) Endowed with anticholeretic, metabolic regulatory, anti-inflammatory, and, potentially, antifibrotic effects, FXR agonists are increasingly also suggested to be involved in vascular homeostasi…”
BackgroundBile acids and their receptors in metabolic disorders
Fiorucci, S., Distrutti, E., Carino, A., Zampella, A., & Biagioli, M. (2021) · Progress in Lipid Research · doi:10.1016/j.plipres.2021.101094 · Cited by 258
Self-citationFarnesoid X receptor targeting to treat nonalcoholic steatohepatitis
Adorini, L., Pruzanski, M., & Shapiro, D. (2012) · Drug Discovery Today · doi:10.1016/j.drudis.2012.05.012 · Cited by 259
Sorribas, M., Jakob, M. O., Yilmaz, B., Li, H., Stutz, D., Noser, Y., de Gottardi, A., Moghadamrad, S., Hassan, M., Albillos, A., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.06.017 · Cited by 253
Lleo, A., Wang, G.-Q., Gershwin, M. E., & Hirschfield, G. M. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31607-x · Cited by 253
Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases
Li, Y., Tang, R., Leung, P. S. C., Gershwin, M. E., & Ma, X. (2017) · Autoimmunity Reviews · doi:10.1016/j.autrev.2017.07.002 · Cited by 247
Verbeke, L., Mannaerts, I., Schierwagen, R., Govaere, O., Klein, S., Vander Elst, I., Windmolders, P., Farre, R., Wenes, M., Mazzone, M., et al. (2016) · Scientific Reports · doi:10.1038/srep33453 · Cited by 236
Copple, B. L., & Li, T. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2015.12.007 · Cited by 235
New therapeutic concepts in bile acid transport and signaling for management of cholestasis
Trauner, M., Fuchs, C. D., Halilbasic, E., & Paumgartner, G. (2017) · Hepatology · doi:10.1002/hep.28991 · Cited by 227
“therapy for cholestatic pruritis,((29)) but limited”
FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity
Wang, X. X., Wang, D., Luo, Y., Myakala, K., Dobrinskikh, E., Rosenberg, A. Z., Levi, J., Kopp, J. B., Field, A., Hill, A., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017020222 · Cited by 222
Non-Alcoholic Steatohepatitis: A Review of Its Mechanism, Models and Medical Treatments
Peng, C., Stewart, A. G., Woodman, O. L., Ritchie, R. H., & Qin, C. X. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.603926 · Cited by 225
“OCA is a farnesoid X receptor (FXR) agonist which regulates the expression of transcription factors that reduce bile acid synthesis and hepatic steatosis (Pellicciari et al., 2002; Jiao et al., 2015).”
BackgroundVerbeke, L., Farre, R., Verbinnen, B., Covens, K., Vanuytsel, T., Verhaegen, J., Komuta, M., Roskams, T., Chatterjee, S., Annaert, P., et al. (2015) · The American Journal of Pathology · doi:10.1016/j.ajpath.2014.10.009 · Cited by 225
Poupon, R. (2012) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/s2210-7401(12)70015-3 · Cited by 222
Baghdasaryan, A., Claudel, T., Gumhold, J., Silbert, D., Adorini, L., Roda, A., Vecchiotti, S., Gonzalez, F. J., Schoonjans, K., Strazzabosco, M., et al. (2011) · Hepatology · doi:10.1002/hep.24537 · Cited by 221
Recent advances in the development of farnesoid X receptor agonists.
Ali, A. H., Carey, E. J., & Lindor, K. D. (2015) · PubMed · doi:10.3978/j.issn.2305-5839.2014.12.06 · Cited by 221
“In a Wistar rat model of cholestasis, OCA promoted bile flow and protected the hepatocytes against acute necrosis caused by administration of LCA (101).”
BackgroundInfluentialMetabolic Messengers: bile acids
Perino, A., & Schoonjans, K. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00559-z · Cited by 223
Intestinal absorption of bile acids in health and disease
Ticho, A. L., Malhotra, P., Dudeja, P. K., Gill, R. K., & Alrefai, W. A. (2019) · Comprehensive physiology · doi:10.1002/cphy.c190007 · Cited by 215
Targeting nuclear receptors for the treatment of fatty liver disease
Tanaka, N., Aoyama, T., Kimura, S., & Gonzalez, F. J. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.05.011 · Cited by 212
“Obeticholic acid (OCA, also known as INT-747), a 6α-ethyl derivative of chenodeoxycholic acid (CDCA), is the first-in-class selective FXR agonist that is approximately 100-fold potent than CDCA for FXR activation (Pellicciari et al., 2002).”
BackgroundDiagnosis and Management of Primary Biliary Cholangitis
Younossi, Z. M., Bernstein, D., Shiffman, M. L., Kwo, P., Kim, W. R., Kowdley, K. V., & Jacobson, I. M. (2019) · American Journal of Gastroenterology · doi:10.1038/s41395-018-0390-3 · Cited by 211
“Therefore, FXR is a critical regulator in bile formation and enterohepatic circulation and as such plays a crucial role in bile acid homeostasis and hepatic regeneration, among other things [135].”
BackgroundInfluentialFXR signaling in metabolic disease
Zhang, Y., & Edwards, P. A. (2008) · FEBS Letters · doi:10.1016/j.febslet.2007.11.015 · Cited by 209
“The development of potent, specific FXR agonists, such as GW4064 [21], fexaramine [22], AGN34 [23] and 6a-ethyl-chenodeoxycholic acid (6-ECDCA) [24], and the generation of FXR-deficient mice [25] have provided powerful tools to inves-”
BackgroundDissecting fibrosis: therapeutic insights from the small-molecule toolbox
Nanthakumar, C. B., Hatley, R. J. D., Lemma, S., Gauldie, J., Marshall, R. P., & Macdonald, S. J. F. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4592 · Cited by 208
Novel therapeutic targets for cholestatic and fatty liver disease
Trauner, M., & Fuchs, C. D. (2022) · Gut · doi:10.1136/gutjnl-2021-324305 · Cited by 204
Barbier, O., Torra, I. P., Sirvent, A., Claudel, T., Blanquart, C., Duran-Sandoval, D., Kuipers, F., Kosykh, V., Fruchart, J.-C., & Staels, B. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00388-3 · Cited by 204
Rizzo, G., Passeri, D., De Franco, F., Ciaccioli, G., Donadio, L., Rizzo, G., Orlandi, S., Sadeghpour, B., Wang, X. X., Jiang, T., et al. (2010) · Molecular Pharmacology · doi:10.1124/mol.110.064501 · Cited by 195
Pellicciari, R., Costantino, G., Camaioni, E., Sadeghpour, B. M., Entrena, A., Willson, T. M., Fiorucci, S., Clerici, C., & Gioiello, A. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm049904b · Cited by 194
Self-citationTargeting farnesoid X receptor for liver and metabolic disorders
Fiorucci, S., Rizzo, G., Donini, A., Distrutti, E., & Santucci, L. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2007.06.001 · Cited by 196
Self-citationFiorucci, S., Clerici, C., Antonelli, E., Orlandi, S., Goodwin, B., Sadeghpour, B. M., Sabatino, G., Russo, G., Castellani, D., Willson, T. M., et al. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.079665 · Cited by 196
“We have previously reported that modification of CDCA by addition of an ethyl group in its position 6 results in a semisynthetic bile acid, the 6-ECDCA, which has potent FXR agonist activity (Pellicciari et al., 2002; Costantino et al., 2003; Mi et al., 2003; Fiorucci et al., 2004).”
BackgroundMethodSelf-citationJones, D., Boudes, P. F., Swain, M. G., Bowlus, C. L., Galambos, M. R., Bacon, B. R., Doerffel, Y., Gitlin, N., Gordon, S. C., Odin, J. A., et al. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30246-7 · Cited by 191
FXR agonists in NASH treatment
Adorini, L., & Trauner, M. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.034 · Cited by 184
Wang, X. X., Jiang, T., Shen, Y., Caldas, Y., Miyazaki-Anzai, S., Santamaria, H., Urbanek, C., Solis, N., Scherzer, P., Lewis, L., et al. (2010) · Diabetes · doi:10.2337/db10-0019 · Cited by 186
Fiorucci, S., Rizzo, G., Antonelli, E., Renga, B., Mencarelli, A., Riccardi, L., Orlandi, S., Pruzanski, M., Morelli, A., & Pellicciari, R. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.084905 · Cited by 183
“FXR is expressed by HSCs, and FXR ligands function as negative regulators of 1(I)collagen synthesis both in vitro and in vivo in rodent models of liver fibrosis (Pellicciari et al., 2002; Mi et al., 2003; Fiorucci et al., 2004), though the mechanism(s) is still not completely understood.”
BackgroundMethodInfluentialSelf-citationTrauner, M., Nevens, F., Shiffman, M. L., Drenth, J. P. H., Bowlus, C. L., Vargas, V., Andreone, P., Hirschfield, G. M., Pencek, R., Malecha, E. S., et al. (2019) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(19)30094-9 · Cited by 180
Wang, X. X., Jiang, T., Shen, Y., Adorini, L., Pruzanski, M., Gonzalez, F. J., Scherzer, P., Lewis, L., Miyazaki-Anzai, S., & Levi, M. (2009) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00404.2009 · Cited by 178
“INT-747 is a high-affinity, semisynthetic, bile acid-derived FXR agonist (33).”
BackgroundMethodFiorucci, S., Rizzo, G., Antonelli, E., Renga, B., Mencarelli, A., Riccardi, L., Morelli, A., Pruzanski, M., & Pellicciari, R. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.085597 · Cited by 177
“6-α-ethyl-chenodeoxycholic acid (6-ECDCA) was synthesized as described previously (Pellicciari et al., 2002; Mi et al., 2003).”
MethodSelf-citationFarnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration
Li, Y. T. Y., Swales, K. E., Thomas, G. J., Warner, T. D., & Bishop-Bailey, D. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.152694 · Cited by 171
Walters, J. R. F., Johnston, I. M., Nolan, J. D., Vassie, C., Pruzanski, M. E., & Shapiro, D. A. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12999 · Cited by 165
“More potent FXR agonists have been synthesised with the aim of treating liver and other disorders.(16) Obeticholic acid (OCA, also known as 6a-ethyl-CDCA and INT–747) is about 100-fold more potent an FXR agonist than CDCA.”
BackgroundFlatt, B., Martin, R., Wang, T.-L., Mahaney, P., Murphy, B., Gu, X.-H., Foster, P., Li, J., Pircher, P., Petrowski, M., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm8014124 · Cited by 163
Ichikawa, R., Takayama, T., Yoneno, K., Kamada, N., Kitazume, M. T., Higuchi, H., Matsuoka, K., Watanabe, M., Itoh, H., Kanai, T., et al. (2012) · Immunology · doi:10.1111/j.1365-2567.2012.03554.x · Cited by 161
Trauner, M., Wagner, M., Fickert, P., & Zollner, G. (2005) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000155551.37266.26 · Cited by 164
Pockros, P. J., Fuchs, M., Freilich, B., Schiff, E., Kohli, A., Lawitz, E. J., Hellstern, P. A., Owens‐Grillo, J., Van Biene, C., Shringarpure, R., et al. (2019) · Liver International · doi:10.1111/liv.14209 · Cited by 160
Rizzo, G., Sante, M. D., Mencarelli, A., Renga, B., Gioiello, A., Pellicciari, R., & Fiorucci, S. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.023820 · Cited by 169
“However, it is unlike that such mechanism explains the counter-regulatory effect of guggulsterone in this experimental setting, taking into account that INT-747 has no activity on the glucocorticoid receptor (Pellicciari et al., 2002).”
BackgroundSelf-citationFXR and PXR: Potential therapeutic targets in cholestasis
Jonker, J. W., Liddle, C., & Downes, M. (2011) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2011.06.012 · Cited by 167
“6-ethyl CDCA (6ECDCA) is a modified bile acid with an EC50 for FXR activation of 99 nM [133] (Fig.”
SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis
Zhou, J., Cui, S., He, Q., Guo, Y., Pan, X., Zhang, P., Huang, N., Ge, C., Wang, G., Gonzalez, F. J., et al. (2020) · Nature Communications · doi:10.1038/s41467-019-14138-6 · Cited by 154
Akwabi-Ameyaw, A., Bass, J. Y., Caldwell, R. D., Caravella, J. A., Chen, L., Creech, K. L., Deaton, D. N., Jones, S. A., Kaldor, I. W., Liu, Y., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.06.073 · Cited by 154
Self-citationCaron, S., Samanez, C. H., Dehondt, H., Ploton, M., Briand, O., Lien, F., Dorchies, E., Dumont, J., Postic, C., Cariou, B., et al. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01004-12 · Cited by 174
RORα controls hepatic lipid homeostasis via negative regulation of PPARγ transcriptional network
Kim, K., Boo, K.-J., Yu, Y. S., Oh, S. K., Kim, H.-K., Jeon, Y., Bhin, J., Hwang, D., Kim, K. I., Lee, J.-S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00215-1 · Cited by 166
Multi-Target Approaches in Metabolic Syndrome
Lillich, F. F., Imig, J. D., & Proschak, E. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.554961 · Cited by 178
“, obeticholic acid (6α-ethyl-chenodeoxycholic acid OCA, 6-EDCA, 5) (Pellicciari et al., 2002), and second non-steroidal compounds, such as the isoxazole derivative GW4064 (6) (Maloney et al.”
BackgroundXu, J., Li, Y., Chen, W.-D., Xu, Y., Yin, L., Ge, X., Jadhav, K., Adorini, L., & Zhang, Y. (2013) · Hepatology · doi:10.1002/hep.26714 · Cited by 160
Higuchi, H., Grambihler, A., Canbay, A. E., Bronk, S. F., & Gores, G. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m309476200 · Cited by 140
Bile Acid-Activated Receptors: A Review on FXR and Other Nuclear Receptors
Shin, D., & Wang, L. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_236 · Cited by 149
Inflammation and fibrogenesis in steatohepatitis
Fujii, H., & Kawada, N. (2012) · Journal of Gastroenterology · doi:10.1007/s00535-012-0527-x · Cited by 154
Revealing the macromolecular targets of complex natural products
Reker, D., Perna, A. M., Rodrigues, T., Schneider, P., Reutlinger, M., Mönch, B., Koeberle, A., Lamers, C., Gabler, M., Steinmetz, H., et al. (2014) · Nature Chemistry · doi:10.1038/nchem.2095 · Cited by 135
Metadata
- Authors
- Pellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M.
- Affiliations
- University of Perugia (IT)
- Corresponding author
- Pellicciari, Roberto
- ORCID
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2002-07-20
- Volume
- 45
- Issue
- 17
- Pages
- 3569-3572
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2049515100
- Cited by
- 743
- References
- 15
- Citations by year
- 2026: 20 · 2025: 33 · 2024: 32 · 2023: 33 · 2022: 46 · 2021: 47 · 2020: 54 · 2019: 46 · 2018: 52 · 2017: 60 · 2016: 49 · 2015: 38 · 2014: 35 · 2013: 27 · 2012: 31
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- farnesoid X receptor agonist, cholestasis, bile acid synthesis inhibition, receptor selectivity
- MeSH terms
- Receptor, Farnesoid X-Activated, Animals, Anticholesteremic Agents, Cell Line, Chenodeoxycholic Acid, Cholestasis, DNA-Binding Proteins, Humans, Ligands, Liver, Structure-Activity Relationship, Transcription Factors, Rats, Wistar, Receptors, Cytoplasmic and Nuclear, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.